Adi Mor - Nov 16, 2022 Form 4 Insider Report for Chemomab Therapeutics Ltd. (CMMB)

Role
Chief Scientific Officer, Director
Signature
/s/ David S. Glatt, Attorney-in-Fact for Adi Mor and Kobi George.
Stock symbol
CMMB
Transactions as of
Nov 16, 2022
Transactions value $
-$1,213,402
Form type
4
Date filed
11/17/2022, 03:56 PM
Next filing
Jan 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CMMB American Depositary Shares Sale -$677K -325K -50% $2.08 325K Nov 16, 2022 Direct F1, F2
transaction CMMB American Depositary Shares Sale -$536K -257K -50% $2.08 257K Nov 16, 2022 By Spouse F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMMB Option to Purchase American Depositary Shares Award $0 +132K $0.00 132K Mar 15, 2018 American Depositary Shares 132K $1.49 Direct F1, F3, F4
transaction CMMB Option to Purchase American Depositary Shares Award $0 +33.7K $0.00 33.7K Oct 28, 2016 American Depositary Shares 33.7K $0.80 By Kobi George, the Reporting Person's spouse F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
F2 The reported price in Column 4 is a weighted average price pursuant to the share purchase agreement between Adi Mor, Kobi George, and the Issuer, as disclosed in the Issuer's Form 8-K filed with the Securities and Exchange Commission on November 16, 2022.
F3 No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
F4 These options have vested and are exercisable as of the date hereof.
F5 These options have vested and are exercisable as of the date hereof, subject to the Reporting Person's continued service.